RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 HspB5 Improves MRI Lesions and Clinical Relapse in RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 16
OP 16
DO 10.1177/155989771429013
UL http://mdc.sagepub.com/content/14/29/16.abstract
AB In patients with relapsing-remitting multiple sclerosis (RRMS), bimonthly injection with low-dose aB-crystallin (HspB5) resulted in a decrease in gadolinium-enhancing (Gd+) lesions and clinical relapses as compared with the placebo. This article presents data from a randomized study [2011-004475-36; van Noort JM et al. ACTRIMS/ECTRIMS 2014 (poster P082)] that evaluated HspB5 for the treatment of RRMS.